UU8 Stock Overview

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. More details

UU8 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($925K)

Earnings are forecast to decline by an average of 10.7% per year for the next 3 years

Significant insider selling over the past 3 months

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Neurogene Inc. Competitors

2invest

XTRA:2INV

€68.9m

Formycon

XTRA:FYB

€416.7m

Heidelberg Pharma

XTRA:HPHA

€144.5m

Biotest

XTRA:BIO3

€1.4b

Price History & Performance

Summary of share price highs, lows and changes for Neurogene
Historical stock prices
Current Share Price	US$7.92
52 Week High	US$39.33
52 Week Low	US$7.75
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-78.80%

Recent updates

Shareholder Returns

	UU8	DE Biotechs	DE Market
7D	0%	0.6%	1.7%
1Y	n/a	-12.2%	12.8%

Return vs Industry: Insufficient data to determine how UU8 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how UU8 performed against the German Market.

Price Volatility

Is UU8's price volatile compared to industry and market?
UU8 volatility
UU8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.9%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: UU8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine UU8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	107	Rachel McMinn	www.neurogene.com

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.

Neurogene Inc. Fundamentals Summary

How do Neurogene's earnings and revenue compare to its market cap?
UU8 fundamental statistics
Market cap	€164.03m
Earnings (TTM)	-€66.22m
Revenue (TTM)	€815.20k

201.2x

P/S Ratio

-2.5x

P/E Ratio

Is UU8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UU8 income statement (TTM)
Revenue	US$925.00k
Cost of Revenue	US$4.51m
Gross Profit	-US$3.58m
Other Expenses	US$71.56m
Earnings	-US$75.14m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.27
Gross Margin	-387.35%
Net Profit Margin	-8,123.68%
Debt/Equity Ratio	0%

How did UU8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 11:24
End of Day Share Price	2025/04/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurogene Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Evan Seigerman	BMO Capital Markets Equity Research
Keith Tapper	BMO Capital Markets Equity Research

Neurogene BST:UU8 Stock Report